Margaret Lawson

Senior Scientist, CHEO Research Institute

Dr. Margaret Lawson is a pediatric endocrinologist at CHEO, Senior Investigator at the CHEO Research Institute, and Professor of Pediatrics at the University of Ottawa. Her research focuses on type 1 diabetes in children and youth, its prevention, and its management – particularly the use of technologies such as insulin pump therapy and continuous glucose monitoring. Her other main research interest focuses on acquiring evidence about the medical, social and family outcomes of hormone intervention for transgender and gender non binary youth.

Related News

Research Projects

  1. Pubertal Suppression, Bone Mass and Body Composition in Youth with Gender Dysphoria


    The majority of transgender youth had vitamin D insufficiency or deficiency with baseline status associated with bone mineral density. Vitamin D supplementation should be considered for all youth with GD.

  2. Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial


    CGM adherence was higher after 6 months when initiated at same time as pump therapy compared to starting CGM 6 months after pump therapy. Greater CGM adherence was associated with improved HbA1c.

  3. Barriers and Facilitators of Pediatric Shared Decision-Making: A Systematic Review


    Our findings can be used to identify potential pediatric SDM barriers and facilitators, guide context-specific barrier and facilitator assessments, and inform interventions for implementing SDM in pediatric practice.

  4. Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial


    Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 1 diabetes.

  5. New Intrauterine Growth Curves Based on United States Data


    Final sample included 257 855 singleton infants (57.2% male) who survived to discharge.